SCHEMBL119472

SCHEMBL119472

O=C(N[C@H](Cc1ccc(C(=O)c2ccccc2)cc1)C(=O)O)OCC1c2ccccc2-c2ccccc21

nearest known ligand 0.60

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
MDM4 O15151 3/20 0.53
TP53 P04637 3/20 0.53
PPARG P37231 1/20 0.49
PPARA Q07869 1/20 0.49
CASP3 P42574 2/20 0.48
TLR2 O60603 2/20 0.47
MDM2 Q00987 4/20 0.47
KMT2A Q03164 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL119699 1.00 MDM4 (0.53) MDM4TP53PPARGPPARACASP3
SCHEMBL29398558 1.00 MDM4 (0.53) MDM4TP53PPARGPPARACASP3
SCHEMBL29402444 1.00 MDM4 (0.53) MDM4TP53PPARGPPARACASP3
SCHEMBL10622470 1.00 MDM4 (0.53) MDM4TP53PPARGPPARACASP3
Water SCHEMBL5158697 0.99 MDM4 (0.52) MDM4TP53PPARGPPARACASP3
SCHEMBL8415223 0.95 MDM4 (0.51) MDM4TP53PPARGPPARACASP3
SCHEMBL7316241 0.92 MDM4 (0.54) MDM4TP53CASP3TLR2MDM2
SCHEMBL1228254 0.91 MDM4 (0.59) MDM4TP53CASP3MDM2KMT2A
SCHEMBL118169 0.91 MDM4 (0.59) MDM4TP53CASP3MDM2KMT2A
SCHEMBL119455 0.91 MDM4 (0.59) MDM4TP53CASP3MDM2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250325508-A1 MODULATORS OF PROTEASOME DYNAMICS AND/OR FUNCTION, COMPOSITIONS, METHODS, AND THERAPEUTIC USES THEREOF TECHNION RES & DEV FOUNDATION (IL) 2025-10-23 US disclosed
US-20230330064-A1 TYROSINE, TRYPTOPHAN AND PHENYLALANINE AS mTOR AGONISTS MEDIATING PROTEASOME DYNAMICS, COMPOSITIONS, METHODS AND USES THEREOF IN THERAPY, AND PROGNOSTIC METHODS FOR DRUG-RESISTANCE RAMBAM MED-TECH LTD. (IL) 2023-10-19 US disclosed
US-8895231-B2 Patterning process and resist composition SHIN-ETSU CHEMICAL CO., LTD. (JP) 2014-11-25 US disclosed
US-8895231-B2 Patterning process and resist composition SHIN-ETSU CHEMICAL CO., LTD. (JP) 2014-11-25 US disclosed
US-8343928-B2 Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus SEATTLE GENETICS, INC. (US) 2013-01-01 US disclosed
US-20120058428-A1 PATTERNING PROCESS AND RESIST COMPOSITION SHIN-ETSU CHEMICAL CO., LTD. (JP) 2012-03-08 US disclosed
US-20120058428-A1 PATTERNING PROCESS AND RESIST COMPOSITION SHIN-ETSU CHEMICAL CO., LTD. (JP) 2012-03-08 US disclosed
US-20090018086-A1 Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus SEATTLE GENETICS, INC. (US) 2009-01-15 US disclosed
US-4762881-A Photoreactive benzoylphenylalanines and related peptides E. I. DU PONT DE NEMOURS AND COMPANY (US) 1988-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230330064-A1 TYROSINE, TRYPTOPHAN AND PHENYLALANINE AS mTOR AGONISTS MEDIATING PROTEASOME DYNAMICS, COMPOSITIONS, METHODS AND USES THEREOF IN THERAPY, AND PROGNOSTIC METHODS FOR DRUG-RESISTANCE RPTOR, PSMG3, MTOR MDM4 1267/4885TP53 106/4885PPARG 3307/4885
US-20250325508-A1 MODULATORS OF PROTEASOME DYNAMICS AND/OR FUNCTION, COMPOSITIONS, METHODS, AND THERAPEUTIC USES THEREOF PSMC1, PSME3, PSMA6 MDM4 1440/4885TP53 595/4885PPARG 3376/4885
US-20090018086-A1 Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus MMAB, DNPEP, MARCKS MDM4 664/4885TP53 1164/4885PPARG 4557/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.